迪哲医药11月11日获融资买入696.10万元，融资余额1.66亿元

Core Viewpoint - Dize Pharmaceutical experienced a decline of 1.11% in stock price on November 11, with a trading volume of 112 million yuan, indicating a challenging market environment for the company [1]. Financing Summary - On November 11, Dize Pharmaceutical had a financing buy-in amount of 6.961 million yuan and a financing repayment of 8.1604 million yuan, resulting in a net financing buy of -1.1994 million yuan [1]. - The total financing and securities balance for Dize Pharmaceutical as of November 11 is 166 million yuan, which accounts for 0.62% of its circulating market value, indicating a high level compared to the past year [1]. - The company had a financing balance of 166 million yuan, which is above the 70th percentile level over the past year [1]. - In terms of securities lending, Dize Pharmaceutical repaid 200 shares on November 11, with no shares sold, and the remaining securities amount to 2,300 shares, with a balance of 137,100 yuan, which is below the 10th percentile level over the past year [1]. Financial Performance - As of September 30, Dize Pharmaceutical had 8,806 shareholders, an increase of 5.01% from the previous period, with an average of 46,528 circulating shares per person, up by 108.97% [2]. - For the period from January to September 2025, Dize Pharmaceutical reported a revenue of 586 million yuan, representing a year-on-year growth of 73.23%, while the net profit attributable to the parent company was -580 million yuan, a decrease of 3.85% year-on-year [2]. - Among the top ten circulating shareholders as of September 30, 2025, Yongying Pharmaceutical Innovation Mixed Fund A ranked fourth with 5.9109 million shares, an increase of 2.2951 million shares from the previous period [2]. - Hong Kong Central Clearing Limited entered as a new sixth-largest circulating shareholder with 4.5066 million shares, while Dongfanghong Medical Upgraded Stock Fund A and Penghua Pharmaceutical Technology Stock A also saw changes in their holdings [2].